| SFDA Approved Use |
Type 2 diabetes mellitus
Empagliflozin is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance - in addition to other medicinal products for the treatment of diabetes Heart failure Empagliflozin is indicated in adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 diabetes mellitus: -to reduce the risk of cardiovascular death and hospitalization for heart failure -to slow kidney function decline Chronic kidney disease Empagliflozin is indicated in adults for the treatment of chronic kidney disease. |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.